Restricted accessLetterFirst published online 2022-5
A letter to the editor,associated with the article entitled “Efficacy and tolerability of combination treatments for major depression: Antidepressants plus second-generation antipsychotics vs esketamine vs lithium” by Vázquez et al. ( Journal of Psychopharmacology,2021,Vol. 35(8) 890–900)
BauerMDell’ossoLKasperS, et al. (2013) Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder. Journal of Affective Disorders151(1): 209–219.
2.
DoréeJPDesRosiersJLewV, et al. (2007) Quetiapine augmentation of treatment-resistant depression: A comparison with lithium. Current Medical Research and Opinion23(2): 333–341.
3.
KandaY (2013) Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplantation48(3): 452–458.
4.
VázquezGHBahjiAUndurragaJ, et al. (2021) Efficacy and tolerability of combination treatments for major depression: Antidepressants plus second-generation antipsychotics vs. esketamine vs. lithium. Journal of Psychopharmacology35(8): 890–900.
5.
YoshimuraRHoriHUmene-NakanoW, et al. (2014) Comparison of lithium, aripiprazole and olanzapine as augmentation to paroxetine for inpatients with major depressive disorder. Therapeutic Advances in Psychopharmacology4(3): 123–129.
